{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-067509","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.287385+00:00","generated_at":"2026-05-16T00:51:56.329022+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Artiva Biotherapeutics appoints Thad Huston as CFO effective Feb 18, 2026","bullets":["Thad Huston appointed CFO, principal financial and accounting officer, effective Feb 18, 2026.","Salary $540,000; discretionary annual cash bonus target of 40% of base salary.","Inducement award of 220,000 RSUs vesting 25% Feb 15, 2027, then quarterly over three years.","Severance: 9 months base salary (non-CIC) or 12 months + full target bonus (CIC), plus COBRA and accelerated vesting.","Huston previously CFO/COO at Galapagos NV and held senior roles at Kite Pharma, LivaNova, and Johnson & Johnson."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-067509","json":"https://secwatch.observer/filing/0001193125-26-067509.json","markdown":"https://secwatch.observer/filing/0001193125-26-067509.md","text":"https://secwatch.observer/filing/0001193125-26-067509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526067509/0001193125-26-067509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526067509/artv-20250128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:51:56.329022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}